XML 52 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 44,319 $ 29,806 $ 80,480 $ 90,633
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 1,000 0 7,000 22,590
Development Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 5,158 5,457 9,050 17,219
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 22,590
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 33 79 128 111
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 1,806 1,746 3,335 6,894
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 2,273 $ 3,352 $ 4,305 $ 9,171